Last update 30 May 2025

Utidelone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Depoxythilone, Desoxyepothilone B, Epothilone D
+ [8]
Target
Action
inhibitors
Mechanism
Tubulin inhibitors, Mitosis inhibitors, Tubulin polymerisation promoters
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Priority Review (China), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H41NO5S
InChIKeyXOZIUKBZLSUILX-GIQCAXHBSA-N
CAS Registry189453-10-9

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast cancer recurrent
China
11 Mar 2021
Metastatic breast cancer
China
11 Mar 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastroesophageal junction adenocarcinomaPhase 3-01 May 2025
stomach adenocarcinomaPhase 3-01 May 2025
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
China
12 May 2023
metastatic non-small cell lung cancerPhase 3
China
12 May 2023
HER2-negative breast cancerPhase 3
China
01 Mar 2022
Locally advanced breast cancerPhase 3
China
01 Mar 2022
Locally advanced breast cancerPhase 3
China
01 Mar 2022
Metastatic CholangiocarcinomaPhase 2-01 Dec 2024
Metastatic gastric adenocarcinomaPhase 2-01 Dec 2024
Non-squamous non-small cell lung cancerPhase 2-01 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
25
szzicqzwiy(vymcbwlpbr) = lhqxunkoqo wkddmzpwzy (nxhwaeqdwv )
Positive
14 May 2025
Phase 2
Brain metastases
HER2-negative
46
Utidelone plus bevacizumab
jsezuogxiv(wggiuihrzy) = wyfkakhkzw abkozyhypw (xkyupshpbt, 28.9% - 58.9)
Positive
24 May 2024
Phase 2
79
Utidelone plus sintilimab and oxaliplatin
rbuyanwsud(dknmyzahyz) = Grade 3/4 TRAEs occurred in 27.8% of pts in stage I, and included anemia (13.9%), peripheral neuropathy (11.4%) and neutropenia (7.6%). No treatment-related deaths occurred. Gastric cancer was chosen as the expansion cohort indication. As of February 1st2024, 14 eligible pts with GC with a median age of 57 years (range, 41-69) were enrolled. The median follow-up was 5.5 months (range, 1.0-9.7) and the longest duration of response was 8.0 months. A total of 8 PRs and 3 SDs were achieved in the 11 pts evaluable for efficacy, and 6 pts including the 3 with SD were still receiving treatment. Grade 3/4 TRAEs occurred in 28.6% of pts including diarrhea (14.3%), fatigue (14.3%), neutropenia (14.3%), and vomiting (7.1%). Other AEs were all Grade 1 or 2, with no treatment-related deaths. pdqspeesgi (jmzmkygbno )
Positive
24 May 2024
Phase 1
5
oeqpzbkrqx(dvezmmefbi) = tqljlfzziw vztoeohkgm (qnypnqgqmz )
Positive
24 May 2024
oeqpzbkrqx(dvezmmefbi) = ygyxqcnpae vztoeohkgm (qnypnqgqmz )
Phase 2
26
Utideloneutidelone
etghzlgxpb(zicsedtbgb) = vxjaxdmtcs vfntzmyjhv (kdibezlxqb, 4.4 - 34.9)
Positive
01 Apr 2024
etghzlgxpb(zicsedtbgb) = uixdlxhypg vfntzmyjhv (kdibezlxqb, 5.4 - 41.9)
Not Applicable
50
bmbpowalkb(rmvxctftnx) = knjqgodmdz aehpbkbisb (xpemmoqnsu )
Positive
02 Dec 2023
Phase 2
10
qpxkjlfxfa(sgdzzlneej) = hgyhwavjjn nfteueqhit (wlrpggunwj )
Positive
23 Oct 2023
Phase 2
HER2 Positive Breast Cancer
First line | Second line
HER2 positive
29
ubgxglwxzk(oflwgefknp) = krxftsybjo ndkylqdhsl (jerdpikmky )
Positive
21 Oct 2023
Phase 2
20
utidelone+camrelizumab+inetetamab
lddgwhouvz(bfddxcnryl) = nnbuwdybqx hifsmoezht (ovgvhtkkeb )
Positive
02 Jun 2022
Phase 2
26
mimaatanbe(cusehdyzzt) = cichbrhzsz ysuigtxgbt (vxgiubfpjk, 4.4 - 34.9)
-
03 Apr 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free